登录 | 注册    关注公众号  
微信公众号
搜索
 > 【FGF-23】

FGF-23信息

英文名称:Fibroblast growth factor 23
中文名称:成纤维细胞生长因子-23
靶点别称:HFTC2,Tumor-Derived Hypophosphatemia Inducing Factor,UNQ3027/PRO9828,Tumor-derived hypophosphatemia-inducing factor,HYPF,FGF23,Fibroblast Growth Factor 23,Phosphatonin,FGF-23,HPDR2,PHPTC,ADHR,FGFN
上市药物数量:1
临床药物数量:0
最高研发阶段:批准上市

FGF-23产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
FG3-H52H3
Human
Human FGF-23 (R179Q) Protein, His Tag
ACRO质量管理体系
 
评论(1)
FG3-H52H3|Human FGF-23 (R179Q) Protein, His Tag
  1. 173XXXXXXX9
  2. 1人赞
  3. 我们要做酶活的检验,之前也买过别家Fgf,非常贵,acro是一个价格合适,效果也很好,纯度也很高,如何配比也写的很详细的品牌!非常不错,用完后会继续回购
  4. >
  5. 2024-05-07
 

FGF-23分子别名

FGF23,HYPF,FGF-23,ADHR,HPDR2

FGF-23分子背景

Fibroblast growth factor 23 (FGF23) is is an endocrine member of the family of FGFs and mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as acting as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3, active vitamin D. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. FGF23 and phosphate have been revealed to be factors relevant in cancer. FGF23 is particularly significant for those forms of cancer primarily affecting bone (e.g., multiple myeloma) or characterized by bone metastasis.

FGF-23上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Burosumab 布罗索尤单抗 KRN-23; UX-023 批准上市 Kyowa Hakko Kirin Co Ltd Crysvita EU 高磷酸盐尿 Kyowa Kirin Holdings Bv 2018-02-19 低磷血症, 骨纤维异常增殖症, 高磷酸盐尿, X连锁遗传病, 骨软化症, 皮脂腺痣, 家族性低血磷性佝偻病 详情

消息提示

请输入您的联系方式,再点击提交!

确定